Advances in the relationship between AP-1 and tumorigenesis, development and therapy resistance

被引:0
|
作者
Xue, Xinni [1 ]
Li, Zhiwei [1 ]
Zhao, Jiahui [2 ]
Zhao, Ziyi [2 ]
Li, Zhihang [2 ]
Li, Yong [2 ]
Liu, Yawen [2 ]
He, Huan [1 ]
机构
[1] Jilin Univ, Sch Publ Hlth, NHC Key Lab Radiobiol, Changchun 130021, Jilin, Peoples R China
[2] Jilin Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Changchun 130021, Jilin, Peoples R China
关键词
AP-1; Tumors; Tumorigenesis; Drug resistance; Radiation resistance; BREAST-CANCER; C-FOS; CELL-PROLIFERATION; TRANSCRIPTION; INHIBITION; EXPRESSION; RECEPTORS; GENE; JUN; RADIOSENSITIVITY;
D O I
10.1007/s12672-025-01783-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activating protein 1 (AP-1) is a transcription factor composed of several protein families, Jun proteins and Fos proteins are the components of AP-1. AP-1 is involved in various cellular processes, such as proliferation, differentiation, apoptosis and inflammation. For tumor cells, AP-1 is considered to be a driver whose activity is associated with dysfunction and the onset, development, invasion, and migration of cancer. In addition, AP-1 has been reported to be involved in the drug resistance and radiation resistance of tumor cells during the treatment process. Therefore, AP-1 is a potential target for cancer therapy. At present, a number of inhibitors targeting AP-1 have been developed and have shown certain anti-cancer effects. However, due to the complex structure and function of AP-1, different structures of AP-1 show different effects in different tumor cells, and more studies are needed to reveal its mechanism of action. This article introduces the relationship between AP-1 and tumor development, summarize the current studies and developments of AP-1 related drugs, and provide the future development values of AP-1.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Spatial and Functional Relationship of GGAs and AP-1 in Drosophila and HeLa Cells
    Hirst, Jennifer
    Sahlender, Daniela A.
    Choma, Maja
    Sinka, Rita
    Harbour, Michael E.
    Parkinson, Michael
    Robinson, Margaret S.
    TRAFFIC, 2009, 10 (11) : 1696 - 1710
  • [22] Interaction between Trypanosoma cruzi factors and AP-1 sequences
    Espinosa, J
    Portal, D
    Martinetto, H
    D'angelo, M
    Torres, H
    Flawiá, M
    FASEB JOURNAL, 1999, 13 (07): : A1506 - A1506
  • [23] Cross-talk between glucocorticoid receptor and AP-1
    Peter Herrlich
    Oncogene, 2001, 20 : 2465 - 2475
  • [24] Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy
    Badarni, Mai
    Prasad, Manu
    Balaban, Noa
    Zorea, Jonathan
    Yegodayev, Ksenia M.
    Ben-Zion, Joshua
    Dinuri, Anat Bahat
    Grenman, Reidar
    Rotblatc, Barak
    Cohen, Limor
    Elkabets, Moshe
    JCI INSIGHT, 2019, 4 (08)
  • [25] Impact of the AP-1 complex component FOSL1 on melanoma development
    Haug, D.
    Haydn, J.
    Spangler, B.
    Bosserhoff, A.
    Schartel, M.
    Meierjohann, S.
    EUROPEAN JOURNAL OF CELL BIOLOGY, 2010, 89 : 53 - 53
  • [26] The AP-1 transcription factor regulates postnatal mammary gland development
    Shen, Qiang
    Zhang, Yun
    Uray, Ivan P.
    Hill, Jamal L.
    Kim, Hee-Tae
    Lu, Chunhua
    Young, Matthew R.
    Gunther, Edward J.
    Hilsenbeck, Susan G.
    Chodosh, Lewis A.
    Colburn, Nancy H.
    Brown, Powel H.
    DEVELOPMENTAL BIOLOGY, 2006, 295 (02) : 589 - 603
  • [27] Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun)
    Wagner, E. F.
    ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 : 86 - 88
  • [28] AP-1 transcription factors in cytotoxic lymphocyte development and antitumor immunity
    Schnoegl, Diana
    Hiesinger, Angela
    Huntington, Nicholas
    Gotthardt, Dagmar
    CURRENT OPINION IN IMMUNOLOGY, 2023, 85
  • [29] Physical and functional cooperation between b-catenin and AP-1
    Toualbi, K
    Mauriz-Guttierez, JL
    Labalette, C
    Legrand, A
    Buendia, MA
    Bernuau, D
    JOURNAL OF HEPATOLOGY, 2005, 42 : 18 - 18
  • [30] Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
    Leaner, Virna D.
    Donninger, Howard
    Birrer, Michael J.
    CURRENT CANCER THERAPY REVIEWS, 2007, 3 (01) : 1 - 6